This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings Update: 'Hold' Healthways

Healthways' cash and cash equivalents plunged 92.0% to $4.35 million from $54.53 million. Net operating cash flow declined 15.0% to $21.65 million when compared to the same quarter last year. Return on assets increased 123 basis points to 6.37% from 5.14%. Similarly, return on equity advanced 377 basis points to 15.33% from 11.56% a year ago. Total debt for the quarter spiked 6.4% to $307.10 million from $288.72 million. Stockholders' equity declined 4.7% to $366.75 million from $384.66 million. Therefore, the debt-to-equity ratio deteriorated to 0.84 from 0.75. Moreover, the company has a quick ratio of 0.75 which shows its inability to meet short-term cash requirements.

During the quarter under review, Healthways signed a new agreement wit a Fortune 100 company to provide comprehensive Health and Care Support solution for more than 90,000 employees and dependents. Also, the company launched new senior solution for the Medicare Advantage population of a large Blue Cross Blue Shield Plan. The company also announced the appointment of Mr. Brueckner to serve as President and Chief Operating Officer.

Recently, the company signed a five-year agreement with the Hospitals Contribution Fund of Australia Limited (HCF) to offer comprehensive Health and Care Support solution.

Looking forward to FY09, the company expects run rate revenue to decline by approximately $90.00 million to $100.00 million over FY08 which would in turn lead to an increase in cost of services and/or selling, general and administrative expenses as a percentage of revenue. In addition, the company also anticipates higher legal expenses.
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HWAY $10.70 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs